Business Wire

MA-HAMAMATSU-PHOTONICS

10.6.2019 05:02:05 CEST | Business Wire | Press release

Share
Hamamatsu Photonics K.K. Has Developed a Novel 3D Fluorescence Scanning Method Called “Zyncscan™“ That Performs an X-Z Plane Scan With a Light-Sheet for Cell-Based Fluorescence Assays in Microplates

Hamamatsu Photonics K.K. (TOKYO:6965) has developed a novel 3D fluorescence scanning method called “Zyncscan™” that performs x-z plane scans using a light-sheet for cell-based fluorescence assays in microplates. This technology provides an x-z plane scan using a light-sheet for a whole 96/384/1536-well microplate, allowing users to obtain 3D fluorescence images of whole wells in xy: 2-3 μm and z: 6-7 μm voxel resolution for ≤ 300 μm thickness from the well bottom within a few minutes per color. This technology also allows for ultra-high level separation of cell fluorescence signals from the background, which makes it possible to obtain fluorescence cell images in the cell culture mediums containing serum and with fluorescent dyes (i.e., no need to wash out fluorescent dyes).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190609005009/en/

Background of development

In drug discovery and development, there is a rapidly growing need to use more physiologically-relevant in vitro cell culture models. These include primary cells, patient-derived cells, human iPSC-derived disease-modeling cells, co-cultures of different types of cells, and 3D cultures such as spheroids and organoids. To develop and advance phenotypic assays and screenings using these physiologically-relevant cellular models, new types of instruments needed to be developed to facilitate high-throughput fluorescence imaging and measurement of heterogeneous 2D and 3D cell cultures. To meet this need, we have developed ZyncscanTM technology that performs an x-z plane scan utilizing a light-sheet for a microplate.

Features of the cell-based fluorescence assays in microplate using Zyncscan™ technology

1)   High-speed fluorescence cytometry for 2D monolayer heterogeneous cell culture
A single 120-second scan (one color) for a whole 96/384/1536-well microplate enables fluorescence cytometry of all individual cells in all wells.
2) Single spheroid analyses using depth information (diameter of spheroid; ≤ 200 μm)
A single scan (in just a few minutes) for a microplate enables fluorescence images of spheroids (single or multiple spheroids in a well) in all wells in a 96/384/1536-well microplate. From the images, the entire fluorescence intensity, thickness and volume of each individual spheroid are estimated.
3) Fluorescence images in 3D view (≤ 300 μm)
With a single scan (a few minutes) obtain 3D fluorescence images (300 μm from the bottom of a well) of all wells in a plate. The optical resolution of the image is comparable with the 2x objective of a conventional fluorescence microscope in the x- and y-axes and a 10x objective of confocal fluorescence microscope in the z-axis.
4) In-medium / No dye washout measurement
Measure cellular fluorescence in the medium containing serum and with fluorescent dyes (no need to wash out fluorescent dyes), allowing cells to remain healthy throughout the experiment.
 

Future outlook

Hamamatsu Photonics K.K. has been developing a fluorescence instrument for cell-based assays equipped with Zyncscan™ technology, CYTOQUBE™, a Light-Sheet Microplate Cytometer. We plan to initiate validation and application experiments in several research sites in drug discovery and development by early 2020. CYTOQUBE™ is planned to be released by the end of the next fiscal year (September 2020).

We will showcase a prototype of the CYTOQUBE™ (Light-Sheet Microplate Cytometer) at the following conferences.

WPC (World Preclinical Congress)
June 17-20, 2019, Boston, MA, USA

https://www.pharmaweek.com/wpc

CYTO
June 22-26, 2019, Vancouver, BC, Canada

http://www.cytoconference.org/2019/Home.aspx

 

Please visit here for more detailed information.
https://www.hamamatsu.com/all/en/news/featured-products_technologies/2019/20190610000000.html

Hamamatsu Photonics K.K.

Hamamatsu Photonics K.K. is a leading manufacturer of photonics devices. We design, manufacture, and sell optical sensors, light sources, optical components, cameras, photometry systems, and measurement/analysis systems.

Web site

https://www.hamamatsu.com

Contact:

Technical Contacts details Hamamatsu Photonics K.K, System Division Business Promotion Department 812, Joko-cho, Higashi-ku, Hamamatsu City, 431-3196 Japan email: export@sys.hpk.co.jp

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

VELOCIFERO Takes Action Against Counterfeiting in China13.11.2026 17:32:00 CET | Press release

White s.r.o., exclusive owner of the VELOCIFERO brand, takes action in China to protect its intellectual property rights. Initial measures in Chongqing and Taizhou have already resulted in the seizure of vehicles alleged to be counterfeit. VELOCIFERO is taking action against counterfeiting in China. White s.r.o., the exclusive owner of the VELOCIFERO brand and its related intellectual property rights, has launched decisive measures to protect its creative and industrial assets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261113797570/en/ Photo courtesy of White s.r.o. “Vehicle sealed in Chongqing as part of actions undertaken to protect VELOCIFERO’s intellectual property rights.” The matter originated in June 2026 when, according to the company’s complaint, computers were removed from the technical office of Taizhou Siweiluo, the company appointed to manufacture VELOCIFERO products. White s.r.o. subsequently became aware

LangChain Raises $300M to Enable Every Company to Own Their Intelligence13.11.2026 16:53:00 CET | Press release

CapitalG leads Series C funding round at a $3B valuation to advance LangChain's agent engineering platform LangChain today announced it has raised $300 million in new funding at a $3 billion valuation, bringing total funding to date to $460 million. The round was led by existing investor CapitalG, with significant participation from new investors GIC and DFJ Growth and existing investors IVP and Sapphire Ventures. LangChain is advancing its mission to help every company own its intelligence. As agents transform the economy, companies are building domain-specific agents differentiated by their knowledge, data, and user experience. These agents will power new products and transform internal company operations, creating lasting competitive advantages for the companies that control them. "Agents are going to transform how companies operate and the products they deliver. The companies that control these systems will build lasting competitive advantages," said Harrison Chase, Co-Founder and

Kinaxis Named a Leader in Five 2026 IDC MarketScapes for Worldwide Supply Chain Planning13.11.2026 13:00:00 CET | Press release

Maestro delivers concurrent planning on a single platform across discrete, process, consumer packaged goods and life sciences Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, today announced it has been named a Leader in five 2026 IDC MarketScape vendor assessments for worldwide supply chain planning. The recognition spans the overall market and four industries - discrete industries, process industries, consumer packaged goods and life sciences industries - all served by a single platform, Kinaxis Maestro®, the company's AI-powered supply chain orchestration platform. "Supply chain leaders don't need a better forecast once a month. They need to know what changed this morning, what it means across the business, and what to do about it," said Andrew Bell, Chief Product Officer of Kinaxis. "I believe being named a Leader across five IDC MarketScape vendor assessments, in industries that plan in very different ways, shows that a single concurr

SBC Medical Announces Capital and Business Alliance with NeuroBrain Dynamics to Advance Clinic Profitability Through Medical AI13.11.2026 12:30:00 CET | Press release

Companies to co-develop six medical AI solutions targeting revenue expansion and cost reduction; SBC Medical secures priority sales rights in Japan and South Korea and targets B2B expansion across Asia SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced a strategic capital and business alliance agreement with NeuroBrain Dynamics Inc. (“NBD”), a Taipei-based company dedicated to enterprise generative AI solutions. As part of the agreement executed on November 13, 2026, SBC Medical has made a minority equity investment in NBD. Through this alliance, SBC Medical plans to introduce two complementary suites of generative AI solutions across its network of 287 clinics in Japan and overseas*: “revenue-growth AI,” to elevate average revenue per visit and customer retention through personalized customer guidance, and “cost-reduction AI,

SBC Medical Group Holdings Reports Third Quarter 2026 Financial Results13.11.2026 12:30:00 CET | Press release

Revenue Up 35%, Net Income Attributable to SBC Medical Up 22%, and Adjusted EBITDA1 Up 66% Year-over-Year; Net Income Margin of 27% and Adjusted EBITDA Margin of 47% — Previously Announced Service Fee Revisions and New Clinic Openings Contribute to Revenue Growth and Operating Margin Improvement SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields to medical institutions in Japan and abroad, today announced its consolidated financial results for the third quarter of fiscal year 2026 (the three months ended September 30, 2026) and the three cumulative quarters of fiscal year 2026 (the nine months ended September 30, 2026). Third Quarter 2026 Financial Highlights Total revenues were $59 million, up 35% year-over-year. Income from operations was $26 million, up 66% year-over-year, with an operating margin of 45%. Net income attributable to SBC Medi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye